SKT analyzes genomic big data based on MetaRunner.
Development of AI algorithms for genome analysis with Geninus
Deriving new drug candidates through discovery of new drug targets


On the 6th, SK Telecom announced that it would develop an "AI-powered human genome analysis algorithm" with genome analysis company Geninus and utilize it to identify new drug targets. A new drug target is a gene or protein that will be affected by a new drug, and it represents the first step in drug development.

SKT will develop a genome analysis AI algorithm by analyzing genome and clinical big data provided by Geninus based on Meta Learner, an AI automation platform that can develop field-specific optimized AI solutions across various fields.

Geninus, which possesses genome analysis technology based on next-generation sequencing (NGS), selects targets obtained from the analysis results of AI algorithms and derives candidate substances for new drug development. Currently, Geninus is providing a genetic diagnosis service specialized in personalized treatment by utilizing various bioinformatics techniques based on its own genome big data.

Precision human genome analysis is a necessary field for personalized treatment of various diseases such as cancer diagnosis and treatment, myocardial infarction, and dementia. The data produced for precise genetic analysis of a single person amounts to approximately 100 GB, requiring big data analysis using AI.

The two companies plan to initially conduct a precise analysis of the human genome using the single-cell genome analysis AI algorithm developed through this collaboration. This will enable the interpretation of pathological characteristics in various patient organs and peripheral blood samples, and is expected to further facilitate research on various diseases, the development of treatments, and personalized precision medicine.

For example, personalized targeted cancer treatment becomes possible. Recent medical research reveals that even within the same cancer, pathological findings and clinical manifestations vary widely. This means that the genes that undergo mutations often differ, and the effects of these genes often differ. As genome analysis AI algorithms become more sophisticated, the effectiveness of cancer treatment can increase, potentially enabling earlier treatment.

According to the Korea Biotechnology Industry Organization's 'Global Clinical Genomics Analysis Market Trends,' the global clinical genome market size is expected to grow at an average annual rate of 19.8%, from USD 5.5 billion (approximately KRW 6.2 trillion) in 2019 to USD 13.55 billion (approximately KRW 15.3 trillion) in 2024.

Genius CEO Park Woong-yang said, “This collaboration will allow SK Telecom’s AI technology and Genius’s genome big data and NGS-based analysis technology to create synergy,” and added, “We expect that by implementing precision medicine from diagnosis to treatment, we will be able to get one step closer to overcoming incurable diseases, including cancer.”